PsyMed Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/PsyMed Ventures/Activity

PsyMed Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

New Fund

Announced a $25M fund for early-stage mental health, psychedelics, neurotechnology, digital health, and precision psychology startups.

PsyMed Ventures $25M fund

PsyMed Ventures

news.crunchbase.com

Added recently

New Fund

Announced a $25M fund for early-stage psychedelics, mental health, neurotechnology, digital health, and precision psychology startups.

$25M PsyMed Ventures fund

PsyMed Ventures

psychiatrytech.com

Added recently

3 milestones· NOV 2025 – MAR 2026Show all

Milestone

Portfolio company Jimini Health raised $17M in seed funding to scale clinician-supervised AI for behavioral health.

Jimini Health

Jimini Health PsyMed Ventures

medcitynews.comMAR 31, 2026

mobihealthnews.com

MAR 31, 2026

Milestone

Portfolio company Aerska raised a $39M Series A financing led by EQT Dementia Fund and age1.

Aerska

AerskaPsyMed Ventures

finance.yahoo.comFEB 9, 2026

FEB 9, 2026

Milestone

Portfolio companies atai Life Sciences and Beckley Psytech completed their strategic combination to form AtaiBeckley.

ATAI Life Sciences

ATAI Life SciencesBeckley PsytechPsyMed Ventures

ir.ataibeckley.comNOV 5, 2025

nasdaq.com

NOV 5, 2025

Exit

Portfolio company Gilgamesh Pharmaceuticals' bretisilocin program was acquired by AbbVie.

Gilgamesh Pharmaceuticals

Gilgamesh PharmaceuticalsPsyMed Ventures

prnewswire.comOCT 17, 2025

OCT 17, 2025

Investment

Participated in Aerska's $21M seed financing for RNAi medicines targeting neurological diseases.

Aerska

AerskaPsyMed Ventures

finsmes.comOCT 6, 2025

OCT 6, 2025

Exit

Portfolio company Gilgamesh Pharmaceuticals announced AbbVie's acquisition of its bretisilocin program.

Gilgamesh Pharmaceuticals

Gilgamesh PharmaceuticalsPsyMed Ventures

nasdaq.comAUG 25, 2025

AUG 25, 2025

Milestone

Portfolio companies atai Life Sciences and Beckley Psytech announced a planned combination to create a psychedelic mental health therapies company.

ATAI Life Sciences

ATAI Life SciencesBeckley PsytechPsyMed Ventures

ir.ataibeckley.comJUN 2, 2025

JUN 2, 2025

Exit

Portfolio company Beckley Psytech agreed to combine with atai Life Sciences in an all-share transaction.

Beckley Psytech

Beckley PsytechPsyMed Ventures

ir.ataibeckley.comJUN 2, 2025

sec.gov

JUN 2, 2025

3 investments· MAY 2024 – NOV 2024Show all

Investment

Participated in Jimini Health's $8M pre-seed financing for clinician-led AI-supported therapy.

Jimini Health

Jimini Health PsyMed Ventures

globenewswire.comNOV 19, 2024

globenewswire.com

bhbusiness.com

globenewswire.com

NOV 19, 2024

Investment

Participated in Neurode's $3.5M pre-seed funding for a wearable ADHD treatment and tracking headband.

Neurode

Neurode PsyMed Ventures

techcrunch.comSEP 10, 2024

wsgr.com

SEP 10, 2024

Investment

Joined Remepy's $10M seed round, part of $15M total funding for hybrid drug development.

Remepy

Remepy PsyMed Ventures

businesswire.comMAY 1, 2024

finsmes.com

cbinsights.com

calcalistech.com

MAY 1, 2024

Milestone

Portfolio company Alto Neuroscience completed its initial public offering on the NYSE.

Alton Neuroscience

Alton Neuroscience PsyMed Ventures

cooley.comFEB 6, 2024

FEB 6, 2024

Page 1 of 2